Center for Autism and Related Disorders, Kennedy Krieger Institute, Baltimore, USA.
Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, USA.
J Neurodev Disord. 2021 Oct 11;13(1):46. doi: 10.1186/s11689-021-09396-9.
Anxiety disorders are highly prevalent in children and adolescents with autism spectrum disorder and often emerge before the age of 6 years. Yet, only a few studies have examined anxiety treatment for this group. Preliminary evidence from these studies suggests that utilizing cognitive behavioral therapy (CBT) as well as strategies to target intolerance of uncertainty (IU) and parental accommodation, known mechanistic and maintaining factors of anxiety may improve anxiety and optimize outcomes in this age group.
To meet this need, we developed an integrated treatment called DINO Strategies for Anxiety and intolerance of Uncertainty Reduction (DINOSAUR), a 12-week group telehealth treatment for 4- to 6-year-old children with ASD. DINOSAUR works with young children and their parents to deliver CBT along with interventions targeting IU and parental accommodation. In this paper, we first discuss the rationale for developing this treatment and then describe a pilot study of its feasibility and preliminary efficacy.
There is a great need to develop anxiety treatments for young children with ASD. We proposed a novel integrated treatment approach that aims to alter the way young children and parents respond to fear, which could potentially improve short- and long-term mental health outcomes for this age group.
ClinicalTrials.gov NCT04432077 on June 03, 2020.
焦虑障碍在自闭症谱系障碍的儿童和青少年中发病率很高,且通常在 6 岁之前出现。然而,仅有少数研究检查了针对该群体的焦虑症治疗方法。这些研究的初步证据表明,使用认知行为疗法(CBT)以及针对不确定性容忍度(IU)和父母迁就的策略,这些是焦虑症的机制和维持因素,可能会改善该年龄段的焦虑症并优化治疗结果。
为了满足这一需求,我们开发了一种名为 DINO 策略的综合治疗方法,用于减少焦虑和不确定性容忍度(DINOSAUR),这是一种针对 4 至 6 岁自闭症儿童的为期 12 周的团体远程医疗治疗方法。DINOSAUR 与幼儿及其父母合作,提供 CBT 以及针对 IU 和父母迁就的干预措施。在本文中,我们首先讨论了开发这种治疗方法的基本原理,然后描述了其可行性和初步疗效的初步研究。
非常有必要为自闭症儿童开发焦虑症治疗方法。我们提出了一种新的综合治疗方法,旨在改变幼儿及其父母对恐惧的反应方式,这可能会改善该年龄段的短期和长期心理健康结果。
ClinicalTrials.gov NCT04432077,于 2020 年 6 月 3 日注册。